Mechanisms of Clinical Reactivity or Tolerance to Mouse Allergen

对小鼠过敏原的临床反应或耐受机制

基本信息

  • 批准号:
    8308660
  • 负责人:
  • 金额:
    $ 76.63万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-06-11 至 2015-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by investigator): Although there has been a great deal of investigation into the pathogenesis of the allergic immune response, there is very little understanding of how natural allergen exposure influences the ensuing allergen-specific immune responses, and whether atopic disposition modifies allergen exposure-immune response relationships. In the proposed study, an occupational model of allergen exposure will be used to test the overarching hypothesis that the level of natural exposure to mouse allergen influences the subsequent immune responses to the major mouse allergen, Mus m 1, and ultimately, the clinical allergy phenotype. To test these hypotheses, we will continue to follow workers at The Jackson Laboratory (TJL) who are currently enrolled in a prospective cohort study, the JAXCohort Study, and recruit additional new workers into the cohort. The specific aims are as follows: (1) To continue to repeatedly assess mouse allergen exposure, mouse allergen-specific humoral responses, and clinical allergy phenotype in currently and newly enrolled participants; (2) To assess the diversity of IgG, IgG4, and IgE mouse allergen epitope repertoires among current and newly enrolled participants; (3) To assess mouse-specific Tr1 cell frequency in newly enrolled participants; and (4) To assess IgE-mediated function by assessing basophil phenotypes and Mus m 1 uptake by antigen presenting cells in newly IgE-sensitized cohort members. We will examine relationships between allergen exposure levels and these allergen-specific immune responses and clinical allergy phenotype. The proposed prospective cohort study, in a setting in which repeated assessments of personal allergen exposure are feasible, is arguably the best approach to understanding these complex, time- and exposure-dependent relationships. Findings from this study will result in a better understanding of the natural history of allergen exposure and immune responses that will provide a foundation for the development of immunomodulatory strategies aimed at prevention and treatment of allergic diseases. PUBLIC HEALTH RELEVANCE: A more detailed understanding of the relationship between allergen exposure and disease is needed to develop better preventive and treatment strategies. We will take advantage of the ability to study dose-response relationships more precisely in an occupational setting as a model to address this relationship. We will compare aspects of our findings in these workers to people with mouse allergy living with high levels of allergen in inner city Baltimore in the hope that the knowledge gained from this study will provide the foundation upon which to devise preventive and therapeutic interventions in occupational and community settings.
描述(由研究者提供):尽管已经对过敏性免疫反应的发病机理进行了大量研究,但对天然过敏原暴露如何影响随之而来的过敏原特异性免疫反应以及特应性倾向是否改变过敏原暴露于免疫反应的关系,几乎没有了解。在拟议的研究中,将使用过敏原暴露的职业模型来检验总体假设,即自然暴露于小鼠过敏原会影响随后对主要小鼠过敏原的免疫反应,MUS M 1,最终是临床过敏表型。为了检验这些假设,我们将继续关注杰克逊实验室(TJL)的工人,他们目前正在参加一项前瞻性队列研究,JaxCohort研究,并招募更多新工人加入该队列。具体目的如下:(1)继续反复评估小鼠过敏原暴露,小鼠过敏原特异性体液反应以及当前和新招募的参与者的临床过敏表型; (2)评估当前和新招收的参与者中IgG,IgG4和IgE小鼠表位曲目的多样性; (3)评估新招募的参与者中小鼠特异性的TR1细胞频率; (4)通过评估新近含IgE敏感的队列成员中抗原呈现细胞的base粒表型和MUS M 1摄取来评估IgE介导的功能。我们将检查过敏原暴露水平与这些过敏原特异性免疫反应和临床过敏表型之间的关系。拟议的前瞻性队列研究是在对个人过敏原暴露的重复评估的环境中,可以说是理解这些复杂,时间和暴露依赖性关系的最佳方法。这项研究的结果将使人们更好地了解过敏原暴露和免疫反应的自然史,这将为发展旨在预防和治疗过敏性疾病的免疫调节策略提供基础。 公共卫生相关性:需要对过敏原暴露与疾病之间的关系有更详细的了解,以制定更好的预防和治疗策略。我们将利用在职业环境中更精确地研究剂量反应关系的能力,以此作为解决这种关系的模型。我们将将这些工人的发现的各个方面与在巴尔的摩内城过敏原的老鼠过敏的人的各个方面,希望从这项研究中获得的知识为在职业和社区环境中设计预防和治疗性干预措施的基础。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

WAYNE G SHREFFLER其他文献

WAYNE G SHREFFLER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('WAYNE G SHREFFLER', 18)}}的其他基金

2020 Food Allergy Gordon Research Conference and Gordon Research Seminar
2020年食物过敏戈登研究会议暨戈登研究研讨会
  • 批准号:
    9914389
  • 财政年份:
    2019
  • 资助金额:
    $ 76.63万
  • 项目类别:
Immune progression and plasticity in relation to child age
与儿童年龄相关的免疫进展和可塑性
  • 批准号:
    10416402
  • 财政年份:
    2017
  • 资助金额:
    $ 76.63万
  • 项目类别:
Immune progression and plasticity in relation to child age
与儿童年龄相关的免疫进展和可塑性
  • 批准号:
    9308334
  • 财政年份:
    2017
  • 资助金额:
    $ 76.63万
  • 项目类别:
Immune progression and plasticity in relation to child age
与儿童年龄相关的免疫进展和可塑性
  • 批准号:
    10579324
  • 财政年份:
    2017
  • 资助金额:
    $ 76.63万
  • 项目类别:
Regulatory and effector T cells in oral immunotherapy for food allergy
食物过敏口服免疫疗法中的调节性和效应性 T 细胞
  • 批准号:
    8196488
  • 财政年份:
    2011
  • 资助金额:
    $ 76.63万
  • 项目类别:
Mechanisms of Clinical Reactivity or Tolerance to Mouse Allergen
对小鼠过敏原的临床反应或耐受机制
  • 批准号:
    8081806
  • 财政年份:
    2010
  • 资助金额:
    $ 76.63万
  • 项目类别:
Mechanisms of Clinical Reactivity or Tolerance to Mouse Allergen
对小鼠过敏原的临床反应或耐受机制
  • 批准号:
    7783801
  • 财政年份:
    2010
  • 资助金额:
    $ 76.63万
  • 项目类别:
Mechanisms of Clinical Reactivity or Tolerance to Mouse Allergen
对小鼠过敏原的临床反应或耐受机制
  • 批准号:
    8470527
  • 财政年份:
    2010
  • 资助金额:
    $ 76.63万
  • 项目类别:
Mechanisms of peanut (A. hypogaea) glycan adjuvanticity.
花生(A.hypogaea)聚糖佐剂的机制。
  • 批准号:
    7919656
  • 财政年份:
    2009
  • 资助金额:
    $ 76.63万
  • 项目类别:
Mechanisms of oral immunotherapy-induced suppression of type I hypersensitivity.
口服免疫疗法诱导抑制 I 型超敏反应的机制。
  • 批准号:
    8013729
  • 财政年份:
    2008
  • 资助金额:
    $ 76.63万
  • 项目类别:

相似国自然基金

花生主要过敏原 Ara h 3 致敏的结构生物学基础
  • 批准号:
    32372441
  • 批准年份:
    2023
  • 资助金额:
    50 万元
  • 项目类别:
    面上项目
鱼类过敏原小清蛋白广谱性模拟抗原的精准构筑及构效关系研究
  • 批准号:
    32372439
  • 批准年份:
    2023
  • 资助金额:
    50 万元
  • 项目类别:
    面上项目
过敏原特异性Th2记忆前体细胞鉴定及其形成机制研究
  • 批准号:
    82371740
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
白色念珠菌过敏原通过CGRP-IL-21-PIEZO1轴促进T细胞-小胶质细胞-神经元通讯介导瘙痒
  • 批准号:
    82371797
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
过敏原RNA疫苗促进过敏性鼻炎中嗜酸性粒细胞分泌保护素D1诱导Treg产生机制
  • 批准号:
    82371122
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目

相似海外基金

Early life exposure to metal mixtures: impacts on asthma and lungdevelopment
生命早期接触金属混合物:对哮喘和肺部发育的影响
  • 批准号:
    10678307
  • 财政年份:
    2023
  • 资助金额:
    $ 76.63万
  • 项目类别:
ECHO Renewal for the INSPIRE Study Cohort
INSPIRE 研究队列的 ECHO 更新
  • 批准号:
    10745075
  • 财政年份:
    2023
  • 资助金额:
    $ 76.63万
  • 项目类别:
Early Life Pulmonary Infection, Microbiome and Trained Innate Immunity
生命早期肺部感染、微生物组和经过训练的先天免疫
  • 批准号:
    10677304
  • 财政年份:
    2023
  • 资助金额:
    $ 76.63万
  • 项目类别:
Neuronally-driven accumulation of glycolytic MafB+MHCIIhi IMs drive airway allergy
神经元驱动的糖酵解 MafB MHCIIhi IM 积累导致气道过敏
  • 批准号:
    10736048
  • 财政年份:
    2023
  • 资助金额:
    $ 76.63万
  • 项目类别:
Developing RNA Vaccines to Treat Peanut Hypersensitivity
开发治疗花生过敏的 RNA 疫苗
  • 批准号:
    10570339
  • 财政年份:
    2023
  • 资助金额:
    $ 76.63万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了